Epigenetic susceptibility factors for prostate cancer with aging

Prostate

Volumn 73, Issue 16, 2013, Pages 1721-1730

  Damaschke, N A ^a   Yang, B ^a   Bhusari, S ^a   Svaren, J P ^b,c   Jarrard, D F ^a,c,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d University of Wisconsin Health   (United States)

Author keywords

aging; epigenetics; imprinting; methylation; prostate cancer

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; BRCA1 PROTEIN; CARBAMAZEPINE; CDH13 PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; DNA; EPHRIN B2; ETIRACETAM; FOLIC ACID; GLUTATHIONE TRANSFERASE P1; HISTONE; HISTONE DEACETYLASE INHIBITOR; LAMOTRIGINE; MEMBRANE PROTEIN; OSTEONECTIN; OXCARBAZEPINE; POTASSIUM CHANNEL KCNQ1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA 2; SOMATOMEDIN B; SUPEROXIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR NKX2.5; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VALPROIC ACID; VINCLOZOLIN;

AGED; AGING; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CHROMATIN STRUCTURE; COLON; CPG ISLAND; DIET SUPPLEMENTATION; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENE EXPRESSION; GENE TARGETING; GENETIC SUSCEPTIBILITY; GENOME IMPRINTING; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOSS OF IMPRINTING; NONHUMAN; ONCOGENE; PEER REVIEW; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; REVIEW; RISK FACTOR; TISSUE DIFFERENTIATION; TISSUE SECTION; TUMOR CELL; TUMOR SUPPRESSOR GENE;

AGING; EPIGENETICS; IMPRINTING; METHYLATION; PROSTATE CANCER;

AGING; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOMIC IMPRINTING; HISTONES; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84886950579     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22716     Document Type: Review

References (82)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62 (1): 10-29.
2. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD,. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male-patients. J Urol 1993; 150 (2): 379-385.
3. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suñer D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M,. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005; 102 (30): 10604-10609.
4. Epstein JI, Carmichael MJ, Partin AW, Walsh PC,. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: Pathogenetic and clinical implications. J Urol 1994; 151 (6): 1587-1592.
5. Feinberg AP, Tycko B,. The history of cancer epigenetics. Nat Rev Cancer 2004; 4 (2): 143-153.
6. Suvà ML, Riggi N, Bernstein BE,. Epigenetic reprogramming in cancer. Science 2013; 339 (6127): 1567-1570.
7. Berdasco M, Esteller M,. Hot topics in epigenetic mechanisms of aging: 2011. Aging Cell 2012; 11 (2): 181-186.
8. Wang Y, Leung FC,. An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 2004; 20 (7): 1170-1177.
9. Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, Simon I, Yakhini Z, Cedar H,. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol 2009; 16 (5): 564-571.
10. Lopez-Serra L, Esteller M,. Proteins that bind methylated DNA and human cancer: Reading the wrong words. Br J Cancer 2008; 98 (12): 1881-1885.
11. Esteller M,. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8 (4): 286-298.
12. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG,. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68 (21): 8954-8967.
13. Bedford MT, van Helden PD,. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 1987; 47 (20): 5274-5276.
14. Yang B, Sun H, Lin W, Hou W, Li H, Zhang L, Li F, Gu Y, Song Y, Li Q, Zhang F,. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry. Urol Oncol 2011; 31 (5): 628-634.
15. Cho NY, Kim JH, Moon KC, Kang GH,. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch 2009; 454 (1): 17-23.
16. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, Perucho M,. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 2006; 9 (3): 199-207.
17. Kamiyama H, Suzuki K, Maeda T, Koizumi K, Miyaki Y, Okada S, Kawamura YJ, Samuelsson JK, Alonso S, Konishi F, Perucho M,. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 2012; 31 (48): 5029-5037.
18. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G,. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011; 21 (7): 1017-1027.
19. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB,. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7 (4): 536-540.
20. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP,. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998; 58 (23): 5489-5494.
21. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, Iacopetta B,. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006; 94 (4): 593-598.
22. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP,. Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 2007; 13 (13): 3796-3802.
23. Henrique R, Jerõnimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C, Sidransky D,. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: Clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006; 4 (1): 1-8.
24. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA,. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012; 106 (1): 77-84.
25. Vasiljevic̈ N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, Cuzick J, Lorincz AT,. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 2011; 30 (4): 151-161.
26. Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, Kane CJ, Carroll PR, Igawa M, Dahiya R,. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun 2004; 321 (2): 455-461.
27. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC,. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: Potential clinical applications. Clin Cancer Res 2006; 12 (5): 1412-1419.
28. Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, Huang W, Jarrard DF,. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 2013; 15 (4): 399-408.
29. Jones PA, Takai D,. The role of DNA methylation in mammalian epigenetics. Science 2001; 293 (5532): 1068-1070.
30. Horii J, Hiraoka S, Kato J, Harada K, Kuwaki K, Fujita H, Toyooka S, Yamamoto K,. Age-related methylation in normal colon mucosa differs between the proximal and distal colon in patients who underwent colonoscopy. Clin Biochem 2008; 41 (18): 1440-1448.
31. Hiraoka S, Kato J, Horii J, Saito S, Harada K, Fujita H, Kuriyama M, Takemoto K, Uraoka T, Yamamoto K,. Methylation status of normal background mucosa is correlated with occurrence and development of neoplasia in the distal colon. Hum Pathol 2010; 41 (1): 38-47.
32. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A,. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324 (5929): 930-935.
33. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S,. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011; 2 (8): 627-637.
34. Branco MR, Ficz G, Reik W,. Uncovering the role of 5- hydroxymethylcytosine in the epigenome. Nat Rev Genet 2012; 13 (1): 7-13.
35. Chia N, Wang L, Lu X, Senut MC, Brenner C, Ruden DM, Hypothesis: Environmental regulation of 5-hydroxymethylcytosine by oxidative stress. Epigenetics 2011; 6 (7): 853-856.
36. Cortessis VK, Thomas DC, Levine AJ, Breton CV, Mack TM, Siegmund KD, Haile RW, Laird PW,. Environmental epigenetics: Prospects for studying epigenetic mediation of exposure-response relationships. Hum Genet 2012; 131 (10): 1565-1589.
37. Sfanos KS, De Marzo AM,. Prostate cancer and inflammation: The evidence. Histopathology 2012; 60 (1): 199-215.
38. Malins DC, Johnson PM, Wheeler TM, Barker EA, Polissar NL, Vinson MA,. Age-related radical-induced DNA damage is linked to prostate cancer. Cancer Res 2001; 61 (16): 6025-6028.
39. Turk PW, Laayoun A, Smith SS, Weitzman SA,. DNA adduct 8-hydroxyl-2'-deoxyguanosine (8-hydroxyguanine) affects function of human DNA methyltransferase. Carcinogenesis 1995; 16 (5): 1253-1255.
40. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K,. Free radical adducts induce alterations in DNA cytosine methylation. Proc Natl Acad Sci USA 1994; 91 (4): 1261-1264.
41. Bhusari SS, Dobosy JR, Fu V, Almassi N, Oberley T, Jarrard DF,. Superoxide dismutase 1 knockdown induces oxidative stress and DNA methylation loss in the prostate. Epigenetics 2010; 5 (5): 402-409.
42. Giovannucci E,. Epidemiologic studies of folate and colorectal neoplasia: A review. J Nutr 2002; 132 (8 Suppl): 2350S-2355S.
43. Shannon J, Phoutrides E, Palma A, Farris P, Peters L, Forester A, Tillotson CJ, Garzotto M,. Folate intake and prostate cancer risk: A case-control study. Nutr Cancer 2009; 61 (5): 617-628.
44. Wainfan E, Poirier LA,. Methyl groups in carcinogenesis: Effects on DNA methylation and gene expression. Cancer Res 1992; 52 (7 Suppl): 2071s-2077s.
45. Dobosy JR, Fu VX, Desotelle JA, Srinivasan R, Kenowski ML, Almassi N, Weindruch R, Svaren J, Jarrard DF,. A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate. Prostate 2008; 68 (11): 1187-1195.
46. Waterland RA, Jirtle RL,. Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003; 23 (15): 5293-5300.
47. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS,. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006; 66 (11): 5624-5632.
48. Anway MD, Cupp AS, Uzumcu M, Skinner MK,. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005; 308 (5727): 1466-1469.
49. Manikkam M, Tracey R, Guerrero-Bosagna C, Skinner MK,. Plastics derived endocrine disruptors (BPA, DEHP and DBP) induce epigenetic transgenerational inheritance of obesity, reproductive disease and sperm epimutations. PLoS ONE 2013; 8 (1): e55387.
50. Guerrero-Bosagna C, Covert TR, Haque MM, Settles M, Nilsson EE, Anway MD, Skinner MK,. Epigenetic transgenerational inheritance of vinclozolin induced mouse adult onset disease and associated sperm epigenome biomarkers. Reprod Toxicol 2012; 34 (4): 694-707.
51. Horsthemke B,. Mechanisms of imprint dysregulation. Am J Med Genet C Semin Med Genet 2010; 154C (3): 321-328.
52. Babak T, Deveale B, Armour C, Raymond C, Cleary MA, van der Kooy D, Johnson JM, Lim LP,. Global survey of genomic imprinting by transcriptome sequencing. Curr Biol 2008; 18 (22): 1735-1741.
53. Reik W, Walter J,. Genomic imprinting: Parental influence on the genome. Nat Rev Genet 2001; 2 (1): 21-32.
54. McGrath J, Solter D,. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell 1984; 37 (1): 179-183.
55. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR, Feinberg AP,. Loss of IGF2 imprinting: A potential marker of colorectal cancer risk. Science 2003; 299 (5613): 1753-1755.
56. Woodson K, Flood A, Green L, Tangrea JA, Hanson J, Cash B, Schatzkin A, Schoenfeld P,. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst 2004; 96 (5): 407-410.
57. Figueroa JA, Lee AV, Jackson JG, Yee D,. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 1995; 80 (12): 3476-3482.
58. Zuo QS, Yan R, Feng DX, Zhao R, Chen C, Jiang YM, Cruz-Correa M, Casson AG, Kang XD, Han F, Chen T,. Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer. Mol Carcinog 2011; 50 (5): 390-396.
59. Hiura H, Okae H, Kobayash H, Miyauchi N, Sato F, Sato A, Suzuki F, Nagase S, Sugawara J, Nakai K, Yaegashi N, Arima T,. High-throughput detection of aberrant imprint methylation in the ovarian cancer by the bisulphite PCR-Luminex method. BMC Med Genomics 2012; 5: 8.
60. Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG,. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis 2009; 30 (12): 2117-2122.
61. Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB,. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res 1995; 1 (12): 1471-1478.
62. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF,. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 2011; 71 (15): 1621-1630.
63. Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA, Srinivasan R, Berres M, Svaren J, Weindruch R, Jarrard DF,. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 2008; 68 (16): 6797-6802.
64. Herold M, Bartkuhn M, Renkawitz R,. CTCF: Insights into insulator function during development. Development 2012; 139 (6): 1045-1057.
65. Biniszkiewicz D, Gribnau J, Ramsahoye B, Gaudet F, Eggan K, Humpherys D, Mastrangelo MA, Jun Z, Walter J, Jaenisch R,. Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality. Mol Cell Biol 2002; 22 (7): 2124-2135.
66. Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM, Jaenisch R,. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 2005; 8 (4): 275-285.
67. Gu Y, Zhang S, Wu Q, Xu S, Cui Y, Yang Z, Zhao X, Sun B,. Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer. J Exp Clin Cancer Res 2010; 29: 6.
68. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S,. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5 (169): 169ra110.
69. Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway LA, Beltran H, Rubin MA, Elemento O,. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 2013; 15 (4): 373-383.
70. Travers AA, Vaillant C, Arneodo A, Muskhelishvili G,. DNA structure, nucleosome placement and chromatin remodelling: A perspective. Biochem Soc Trans 2012; 40 (2): 335-340.
71. Kouzarides T,. SnapShot: Histone-modifying enzymes. Cell 2007; 128 (4): 802.
72. Behbahani TE, Kahl P, von der Gathen J, Heukamp LC, Baumann C, Gütgemann I, Walter B, Hofstädter F, Bastian PJ, von Ruecker A, Müller SC, Rogenhofer S, Ellinger J,. Alterations of global histone H4K20 methylation during prostate carcinogenesis. BMC Urol 2012; 12: 5.
73. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK,. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435 (7046): 1262-1266.
74. O'Sullivan RJ, Kubicek S, Schreiber SL, Karlseder J,. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol 2010; 17 (10): 1218-1225.
75. So AY, Jung JW, Lee S, Kim HS, Kang KS,. DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. PLoS ONE 2011; 6 (5): e19503.
76. Stettner M, Krämer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC, Thelen P,. Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prev 2012; 21 (1): 55-64.
77. Balakrishnan L, Milavetz B,. Decoding the histone H4 lysine 20 methylation mark. Crit Rev Biochem Mol Biol 2010; 45 (5): 440-452.
78. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, Raederstorff D, Morrow JD, Leeuwenburgh C, Allison DB, Saupe KW, Cartee GD, Weindruch R, Prolla TA,. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008; 3 (6): e2264.
79. Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, Jarrard DF,. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol 2012; 189 (6): 2335-2341.
80. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang BD, Andrawis R, Lee NH, Apprey V, Issa JP, Ittmann M,. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 2010; 16 (14): 3539-3547.
81. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF,. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8 (2): 514-519.
82. Rabiau N, Thiam MO, Satih S, Guy L, Kemeny JL, Boiteux JP, Fontana L, Bignon YJ, Bernard-Gallon D,. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo 2009; 23 (3): 387-391.